Abstracts tagged "Clinical Response"

Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Roy Fleischmann¹, T. W. J. Huizinga², Arthur Kavanaugh³, Bethanie Wilkinson⁴, Kenneth Kwok⁵, Ryan DeMasi⁵ and Ronald F. van Vollenhoven⁶, ¹Metroplex Clinical Research Center, Dallas, TX, ²Leiden University Medical Center, Leiden, Netherlands, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…
Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁵Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
Abstract Number: 475 • 2015 ACR/ARHP Annual Meeting
Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
Arthur Kavanaugh¹, Carol J. Etzel^2,3, Wendi Malley³, Chitra Karki³, Jeffrey D. Greenberg^3,4, Yanjun Bao⁵, Naijun Chen⁵ and Vishvas Garg⁶, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴NYU School of Medicine, New York, NY, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie, North Chicago, IL
Background/Purpose: Based on international task force recommendations, the primary goal of rheumatoid arthritis (RA) treatment is to: achieve control of symptoms to greatest extent possible,…
Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
Abstract Number: 727 • 2015 ACR/ARHP Annual Meeting
Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids
Richard Furie¹, Maya Das², Daner Li², Shanique Smythe², Ericka Mathura² and Patrice Becker², ¹Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ²Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Melanocortins such as corticotropin and alpha-MSH may modulate steroid-independent immune responses relevant to SLE pathophysiology. We previously reported that repository corticotropin injection (RCI), an…
Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
I.M. Markusse¹, G. Akdemir², L. Dirven², M. van den Broek², K.H. Han³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, W.F. Lems^6,7, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…
Abstract Number: 2513 • 2014 ACR/ARHP Annual Meeting
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Chamaida Plasencia-Rodriguez¹, Dora Pascual-Salcedo², Maria Gema Bonilla³, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁴, Pilar Aguado⁵, Teresa Jurado⁶, Emilio Martín-Mola⁷ and Alejandro Balsa⁸, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Immunology, La Paz University Hospital, Madrid, Spain, ³Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁴Hospital La Paz-IdiPaz, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose : There is a close association between serum Infliximab (Ifx) levels and the Antibodies To Infliximab (ATI) with the clinical activity in rheumatoid arthritis…
Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
M. Victoria Hernández¹, Andrea Cuervo¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…
Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
V. Strand¹, A. Dikranian², J. Beal³, K. Kwok³, S. Krishnaswami⁴, S. Wood⁴ and C. Nduaka⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Olga Addimanda¹, Pierluigi Macchioni², Andrea Caruso¹, Niccolò Possemato¹, Mariagrazia Catanoso¹ and Carlo Salvarani², ¹S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…
Abstract Number: 2400 • 2014 ACR/ARHP Annual Meeting
Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Chamaida Plasencia-Rodriguez¹, G. J. Wolbink², Charlotte L. M. Krieckaert², Eva L. Kneepkens³, Samina Turk⁴, Maria Gema Bonilla⁵, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁶, Mike T. Nurmohamed², Theo Rispens⁷, Desiree van der Kleij⁸, Teresa Jurado⁹, Emilio Martín-Mola¹⁰, Dora Pascual-Salcedo¹¹ and Alejandro Balsa¹², ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Sanquin Research, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹¹Immunology, La Paz University Hospital, Madrid, Spain, ¹²Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose: There is a growing interest about optimization of biological therapies but for now no strong evidence is available to support a tapering strategy in…
Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Daniela Opris¹, Diana Mazilu², Violeta Bojinca³, Andreea Borangiu², Andra Balanescu⁴, Denisa Predeteanu⁵ and Ruxandra Ionescu⁴, ¹53 Tineretului Blvd, Bl. 65, s, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ²Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Intr. Carol Knappe Nr. 9A, Sec, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁵Bld.Mircea Voda Nr 36., Bl M6,, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…
Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Eun Young Lee⁸, Francisco G. Medina-Rodriguez⁹, Pavel Shesternya¹⁰, Sebastiao Radominski¹¹, Dong Hyuk Sheen¹², Mie Jin Lim¹³, Jung-Yoon Choe¹⁴, Leysan Myasoutova¹⁵, Taek Kwon¹⁶, Sang Joon Lee¹⁶, Seung-Cheol Shim¹⁷ and Chang-Hee Suh¹⁸, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁹Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹⁰Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹¹CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹²Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁴Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹⁵City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁶CELLTRION, Inc., Incheon, South Korea, ¹⁷Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ¹⁸Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
Abstract Number: 1058 • 2014 ACR/ARHP Annual Meeting
Levels of Fatigue Are Dependent on Country of Residence in Rheumatoid Arthritis: An Analysis Among 3920 Patients from 17 Countries
Monika Hifinger^1,2, Polina Putrik^3,4, Sofia Ramiro^5,6, Maxime Dougados⁷, Laure Gossec⁸, Andras Keszei⁹, Ihsane Hmamouchi¹⁰ and Annelies Boonen¹¹, ¹Rheumatology, University of Maastricht, Maastricht, Netherlands, ²Rheumatology, MUMC, University Hospital Maastricht, Maastricht, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Health Promotion, Maastricht University, Maastricht, Netherlands, ⁵Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁷Cochin Hospital, Paris Descartes University, Paris, France, ⁸Rheumatology, Pierre et Marie Curie University, Paris, France, ⁹Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ¹⁰Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ¹¹Internal Medicine-Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: For patients with rheumatoid arthritis (RA), fatigue is an important aspect of disease which impacts quality of life. However the complex relationship between fatigue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.